Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Infectious Disease/Hepatitis

Infectious Disease

Hepatitis

108

Pipeline Programs↗

144

Active Trials↗

128

Companies Involved↗

Hepatitis is a highly competitive landscape with 108 programs across 128 companies. The most active players are Rivus Pharmaceuticals, Inc., Enyo Pharma, Guangdong Raynovent Biotech Co., Ltd. 23 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

68/100

Mech. Concentration

33/100

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Rivus Pharmaceuticals, Inc.

1 program

Enyo Pharma

1 program

Guangdong Raynovent Biotech Co., Ltd

1 program

Pipeline

Programs by Phase

Preclinical48

Acetaminophen

Kenvue Brands

Hydroxychloroquine

Jazz Pharmaceuticals

Blood Collection

Assistance Publique - Hôpitaux de Paris

Lopinavir/ritonavir

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Plasma Exchange

Sanofi

Phase 17

At-587

Atea Pharmaceuticals, Inc.

SN2001

Chimivac INC

Wgc0201

Jiyan Liu

Nucleos(t)ide Analogue (NA)

Ausper Biopharma Co., Ltd.

Liocyx-M

Lion TCR Pte. Ltd.

Phase 230

Vonafexor

Enyo Pharma

HU6

Rivus Pharmaceuticals, Inc.

Emapalumab

Swedish Orphan Biovitrum

Betaine

RECORDATI GROUP

Epclusa

University of Pennsylvania

Phase 323

N-Acetylcysteine (NAC) Treatment

The First Affiliated Hospital of Soochow University

Hydrochloroquine

National Taiwan University Hospital

N-Acetyl Cyteien

Stanford University

Peginterferon Alfa-2b

Merck & Co.

Brelovitug

Mirum Pharmaceuticals, Inc.

Approved

No programs

Analysis

Modality Breakdown

86%

Small molecule

76 of 88 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 88 classified programs, each share of the total. Modality classified for 95% of 108 pipeline programs.

Analysis

Trial Status

1,344

clinical trials

Completed836 · 62%

Unknown status191 · 14%

Terminated123 · 9%

Recruiting69 · 5%

Withdrawn44 · 3%

Active, not recruiting40 · 3%

Other41 · 3%

Clinical Trials

Trial Activity

1344 trials

A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis

Recruiting· Amgen logo

Amgen·Phase 3·NCT07598825·180 enrolled

Comparison Between Conventional Ultrasound and Remote Ultraportable ulTrasound for Abdominal Examination in the Context of Viral Hepatitis

Recruiting·—·N/A·NCT06571981·102 enrolled

A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

Recruiting·MMirum Pharmaceuticals, Inc.·Preclinical·NCT07454837·120 enrolled

Belimumab in the Management of Autoimmune Hepatitis: A Multi-centre, Open-label Trial of add-on Belimumab Therapy to Standard of Care

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06381453·48 enrolled

A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting·BBrii Biosciences Limited·Phase 2·NCT06650852·250 enrolled

RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)

Recruiting·BBausch Health Americas, Inc.·Phase 3·NCT07428538·350 enrolled

Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis - A Prospective Pilot Study

Recruiting·MMedical University Innsbruck·Phase 2·NCT06582329·16 enrolled

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Recruiting·MMirum Pharmaceuticals, Inc.·Phase 3·NCT07200908·172 enrolled

Single-Center Cohort Study on the Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)

Recruiting·—·N/A·NCT07855029·400 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT07852091·1,200 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT07845058·1,200 enrolled

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of Single and Multiple Ascending Doses of IB-001 in Healthy Participants and Participants With Chronic Hepatitis B

Recruiting·IIntegerBio·Phase 1·NCT07389044·88 enrolled

Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis

Recruiting·TThe Cleveland Clinic·N/A·NCT04088370·30 enrolled

Mechanism of HA35 in Patients With Alcoholic Liver Disease

Recruiting·TThe Cleveland Clinic·Phase 1·NCT05018481·54 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05769816·120 enrolled

Page 1 of 90

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)